We are live on ! Find out more

Structure Therapeutics

GPCR

Market cap $3.51B

49.22 USD

-0.13

0.26%

At close Updated Aug 27, 4:00 PM EDT

Pre-market

After hours

49.40

+0.18

0.37%

1 day

-0.26%

5 days

-2.92%

1 month

1.09%

3 months

24.48%

6 months

-21.85%

Year to date

-27.75%

1 year

159.05%

5 years

89.31%

10 years

89.31%

About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Employees: 281

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 62.5%

Neutral 37.5%

Negative 0%

Zacks Investment Research

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value inflection points despite high R&D burn.

Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Zacks Investment Research

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

The Next Phase Of The Obesity Drug Race

Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Pharma are trying to fight for market share.

The Next Phase Of The Obesity Drug Race

Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)

Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for obesity, supported by strong Phase 2b data. GPCR's $1.5B cash position and a projected cash runway through 2028 underpin its ability to execute pivotal trials and commercial plans. My SOTP analysis yields a fair value of $42.49/share, with aleniglipron's risk-adjusted NPV at $1.34B and pipeline assets included at no additional cost.

Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Structure's experimental obesity pill shows no signs of liver injury

Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the drug.

Structure's experimental obesity pill shows no signs of liver injury

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

Zacks Investment Research

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?

NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.

Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?

See News Rankings

Price charts implemented using Lightweight Charts™